Comparative Pharmacology
Head-to-head clinical analysis: MERETEK UBT KIT W PRANACTIN versus PORCINE SECRETIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MERETEK UBT KIT W PRANACTIN versus PORCINE SECRETIN.
MERETEK UBT KIT (W/ PRANACTIN) vs PORCINE SECRETIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meretek UBT Kit contains [13C]urea; Helicobacter pylori urease hydrolyzes [13C]urea to produce [13C]CO2, which is detected in breath to indicate active H. pylori infection.
Stimulates exocrine pancreatic secretion by acting on secretin receptors on pancreatic ductal cells, increasing bicarbonate and water secretion. Also stimulates bile and gastric acid secretion.
75 mg oral pranactin (citric acid) dissolved in 200 mL water, administered once for urea breath test.
0.2 mcg/kg intravenous bolus over 1 minute, maximum 20 mcg.
None Documented
None Documented
Not applicable; 13C is a stable isotope that is rapidly converted to 13CO2; elimination half-life of CO2 from the body is approximately 5-10 minutes under normal respiratory conditions. Clinical context: 13CO2 appearance in breath peaks at 30 minutes post-dose.
The terminal elimination half-life is approximately 4-6 minutes, reflecting rapid degradation by plasma proteases; this short half-life limits its systemic duration of action and necessitates continuous infusion for sustained secretory testing.
Urea (13C) is rapidly hydrolyzed by H. pylori urease in the stomach to 13CO2, which is absorbed and exhaled via the lungs; >99% of the 13C dose is eliminated as exhaled 13CO2 within 24 hours. Pranactin (citric acid) is metabolized to CO2 and water; <2% renal elimination.
Primarily renal, with over 90% of the administered dose eliminated via glomerular filtration and tubular reabsorption; fecal and biliary excretion are negligible.
Category C
Category C
Diagnostic Agent
Diagnostic Agent